Keytruda | pharmaphorum

Saturday 28 February 2026

Keytruda

News

MSD headquarters

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

Padcev/Keytruda scores again in early bladder cancer

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

Lady Justice in front of German flag

Setback for MSD as German court blocks Keytruda SC launch

A court in Germany has granted an injunction that will prevent MSD from distributing the new, subcutaneous version of its cancer drug Keytruda.

News

EMA starts review of 'transformative' bladder cancer therapy

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

News

MSD, Eisai abandon combination trial in liver cancer

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

News

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.